Anthony Crisman

Managing Director
Chicago Mergers & Acquisitions Healthcare +1 (312) 506-2771
I seek to understand client needs and goals, and work tirelessly to deliver options that achieve outcomes they deserve, while cultivating a relaxed, open and consultative relationship.

Tony leads the firm’s outsourced pharmaceutical services and life sciences practices, specializing in mergers and acquisitions (M&A). He has executed sell-side and buy-side M&A transactions for private equity clients, publicly traded companies and privately held and family-owned businesses.

Tony specializes in M&A for highly differentiated outsourced pharmaceutical service businesses and clinical laboratories, helping them to understand the converging and dynamic end markets, identify growth opportunities and leverage technology to deliver cost-saving solutions. His deep experience in pharmaceutical outsourcing and laboratory markets provides unique insights to assist growing life sciences companies (diagnostics and research products) that supply laboratories, contract research organizations and pharmaceutical / biotechnology companies with the innovative products and technologies required to remain cutting edge.

Prior to joining Lincoln, Tony was a Vice President in the healthcare investment banking practice of GCA Savvian Advisors. Previously, he was an Associate at Vector Securities International and an Analyst in the Healthcare Corporate Finance group of RBC Capital Markets (formerly Dain Rauscher Wessels).

Tony earned a Bachelor of Science from the Carlson School of Management at the University of Minnesota.

Perspectives featuring Anthony Crisman

Discovering the Investment Opportunity in Pre-Clinical CROs

The process to bring a drug to market is likely to be extensive and costly, from the starting points of research and development (R&D) across all phases of clinical trials… Read More

Outsourced Healthcare Logistics: Ripe for Private Equity Investment

Ample consolidation opportunity for private equity (PE) to capitalize on accelerating healthcare trends and consistent well-above GDP growth rates   Favorable market fundamentals supporting the mid-and-long-term outlook for healthcare third-party… Read More

Awakening of the Healthcare Consumer

Since the beginning of the Information Age, there has been discussion around the importance, emergence, and empowerment of the health care consumer. This has been enabled and driven by rapid… Read More

Interim/Post-COVID-19 Sector Outlook: Services & Products for Homebound Patients

Click the home healthcare sectors below to view key takeaways on the effects of COVID-19. Medical and Personal Services Skilled Home Healthcare Near term: REASONABLY STABLE / POSITIVE Long term:… Read More

Showing 1 – 4 of 5
Load More

News & Media featuring Anthony Crisman

Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence

Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.

Scrip | What Does 2023 Hold for Biopharma?

Originally posted by Scrip on January 9, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for biopharma mergers and acquisitions (M&A) trends in 2023. View the… Read More

Showing 1 – 2 of 2

Meet our Senior Team in Healthcare

Firm details on FINRA’s BrokerCheck